Clinical trials: Non Alcoholic Fatty Liver
HIV Infections, Coronary Artery Disease
Coronary Artery Disease and Its Association With Liver Steatosis Among HIV-Infected Persons
The primary purpose of this study is to evaluate the association between nonalcoholic fatty liver disease (NAFLD) by computed tomography (CT) scan and coronary artery disease (CAD) measured by the calcium (CAC) score among…
- Conditions
- HIV Infections, Coronary Artery Disease, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT00889577
- Where
- United States
- Volunteers
- 233 people, healthy volunteers welcome
- Sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
NAFLD
Fighting Fatty Liver in India
This study aims to build capacity in India by: 1. Developing tailored protocol methodologies for research including technical capability in imaging (MRI/S protocols \& customised software), dietary intervention delivery, dietary…
- Trial name
- FFL (NCT03844165)
- Testing
- Diet change (red rice), Yoga
- Where
- India
- Volunteers
- 84 people
- Sponsor
- University of Nottingham
Metabolic Dysfunction-Associated SteatoHepatitis (MASH)
A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
This study is researching an investigational drug, ALN-HSD called "study drug". This study is focused on participants who are known to have Metabolic dysfunction-Associated SteatoHepatitis (MASH).
- Trial name
- NASHGEN-2 (NCT05519475)
- Testing
- ALN-HSD
- Where
- 71 sites in United States, Japan and 2 more
- Volunteers
- 120 people
- Sponsor
- Regeneron Pharmaceuticals
NAFLD
Effect of Mediterranean Diet on Non-alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) is a clinical/biochemical condition associated with the metabolic syndrome. As the disease stems from excess calorie intake and lack of physical activity, the correction of unhealthy…
- Trial name
- Nutriepa (NCT01798719)
- Testing
- Low Glycemic Index Mediterranean Diet, General Advice
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
Visceral Fat, Fatty Liver
Visceral Abdominal Fat, Non Alcoholic Fatty Liver Diseases and Asymptomatic Coronary Atherosclerosis
Visceral fat or peri-omental fat is increasingly associated with metabolic syndrome, a condition carrying a high risk of coronary artery disease. The independent role of Visceral Fat in cardiovascular risk remains unclear.
- Conditions
- Visceral Fat, Fatty Liver, Atherosclerosis, Coronary Computed Tomography Angiography
- Trial name
- NCT01282892
- Testing
- excess of visceral fat, patients with NAFLD
- Where
- 2 sites in Israel
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Ziv Hospital
Carcinoma, Hepatocellular
A Cross Sectional Study Evaluating the Mean Levels of Alpha Fetoprotein in Patients of Hepatocellular Carcinoma and Its Correlates in Pakistan
This study aims to explore the levels of alpha-fetoprotein (AFP), a protein often elevated in liver cancer, in patients with hepatocellular carcinoma (HCC).
- Trial name
- NCT06629857
- Where
- Pakistan
- Volunteers
- 94 people
- Sponsor
- Darul Sehat Hospital
Non-Alcoholic Fatty Liver Disease
The Effect of Probiotics on the Clinical Outcomes and Gut Microenvironment in Patients With Fatty Liver
Fatty liver has been associated with high risk of progression to inflammation of the liver, liver cirrhosis (hardening of the liver), and eventually can lead to liver cancer.
- Trial name
- NCT04074889
- Testing
- (Microbial cell preparation) Probiotics
- Where
- Malaysia
- Volunteers
- 48 people
- Sponsor
- Universiti Kebangsaan Malaysia Medical Centre
Nonalcoholic Steatohepatitis (NASH)
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)
This phase 1b, Open-Label Study is to assess the safety, efficacy of miricorilant in patients with presumed Nonalcoholic Steatohepatitis (NASH)
- Trial name
- NCT05117489
- Testing
- Miricorilant 150 mg, Miricorilant 100 mg, Miricorilant 50 mg
- Where
- 9 sites in United States
- Volunteers
- 70 people
- Sponsor
- Corcept Therapeutics
Non-Alcoholic Fatty Liver Disease
The Nijmegen-Leiden-Amsterdam 2-tiered Care Path Study
Non-alcoholic fatty liver disease (NAFLD) is a liver disease, caused by storage of fat in the liver. The most-important risk-factors are being overweight, and disorders in sugar and cholesterol handling of the body.
- Trial name
- NLA2 (NCT05712603)
- Testing
- FIB4-score, Vibration controlled transient elastography, Enhanced Liver Fibrosis test
- Where
- 3 sites in Netherlands
- Volunteers
- 655 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Metabolic Dysfunction Associated Steatohepatitis
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
This study is open to adults who are at least 18 years old and have: A confirmed liver disease called non-alcoholic steatohepatitis (NASH) or A confirmed liver disease called metabolic-associated steatohepatitis (MASH) BMI of 27…
- Trial name
- NCT06632457
- Testing
- Survodutide
- Where
- 447 sites in United States, Argentina and 35 more
- Volunteers
- 1,590 people
- Sponsor
- Boehringer Ingelheim
Total Pancreatectomy, Pancreaticoduodenectomy
Hepatic Histology and Metabolism Following Total Pancreatectomy and Pancreaticoduodenectomy
The objective of the study is to investigate the development of NAFLD following total pancreatectomy and pancreaticoduodenectomy and to explore the histological and metabolic changes following the procedures.
- Conditions
- Total Pancreatectomy, Pancreaticoduodenectomy, Pancreatic Diabetes, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT03864744
- Where
- Denmark
- Volunteers
- 33 people
- Sponsor
- Steno Diabetes Center Copenhagen
Nonalcoholic Fatty Liver Disease
Prospective Cohort, With Biobanking, of Patients With Nonalcoholic Fatty Liver Disease
The aim of the present prospective NAFLD cohort study (with biobank), of obese subjects with proven NAFLD based on liver biopsy and/or MRI, is to study factors contributing to the development of NASH in patients with simple…
- Trial name
- NAFLD-cohort (NCT02422238)
- Where
- Netherlands
- Volunteers
- 500 people
- Sponsor
- Maastricht University Medical Center
Pediatric Non-alcoholic Fatty Liver Disease
Comparison Between the Efficacy of Residential and Ambulatory Weight Loss Programs for Pediatric Non-alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) has become the most prevalent chronic liver disease worldwide, paralleling the obesity pandemic.
- Trial name
- NCT05309863
- Testing
- Lifestyle management
- Where
- 3 sites in Belgium
- Volunteers
- 850 people
- Sponsor
- University Hospital, Ghent
NASH With Fibrosis, NAFLD
AGED Diagnostics Liver Disease Assessment
Continue development of previously established methods to further validate candidate biomarkers that can discriminate steatosis from NASH and separately stage fibrosis from blood.
- Conditions
- NASH With Fibrosis, NAFLD, Healthy
- Trial name
- AGEDDX (NCT06348563)
- Testing
- AGED Multiple Target Assay in Healthy Controls, AGED Multiple Target Assay in NAFLD Participants, AGED Multiple Target Assay in Fibrosis Participants
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Active Genomes Expressed Diagnostics, Corp
Nonalcoholic Fatty Liver Disease
Saroglitazar Magnesium 4 mg for Nonalcoholic Fatty Liver Disease (NAFLD) in People Living With HIV in the US
Saroglitazar Magnesium 4 mg for NAFLD in People Living with HIV in the US
- Trial name
- SARONAPLUS (NCT05211284)
- Testing
- Saroglitazar Magnesium 4 mg
- Where
- 8 sites in United States
- Volunteers
- 4 people
- Sponsor
- Zydus Therapeutics Inc.
Non-alcoholic Fatty Liver Disease (NAFLD)
Validation Study of the Velacur System in Comparison to MRE & MRI-PDFF in Patients With (Suspected) Liver Disease
The goal of this open-label, non-randomized, prospective study is to compare Velacur and MRE in all sexes, 18-80 years old with Non-Alcoholic Fatty Liver Disease (NAFLD).
- Trial name
- NCT05908006
- Testing
- Velacur
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- GI Alliance
End Stage Liver Disease, NASH - Nonalcoholic Steatohepatitis
Tocotrienol Against the Progression of End Stage Liver Disease
The purpose of this Phase 2 trial is to validate the outcome observed in a previous trial that oral Tocotrienol (TCT) attenuates the rise in MELD score over time in patients with end stage liver disease / cirrhosis.
- Conditions
- End Stage Liver Disease, NASH - Nonalcoholic Steatohepatitis, NAFLD - Nonalcoholic Fatty Liver Disease
- Trial name
- NCT02581085
- Testing
- Tocotrienol (TCT)
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Chandan Sen
Obesity, Diabetes Mellitus, Type 2
Bariatric Surgery-Induced Shift in Gut Microbiome and NAFLD
This study is designed as a prospective pilot study for longitudinal assessment of fecal microbiome related to medical and surgical weight loss.
- Conditions
- Obesity, Diabetes Mellitus, Type 2, NAFLD
- Trial name
- NCT04263376
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- The Cleveland Clinic
Nonalcoholic Fatty Liver Disease, Physician
Patient and Physician Perspectives on Non-Alcoholic Fatty Liver Disease
This trial studies patient and physician perspectives on non-alcoholic fatty liver disease. Using questionnaires and interviews, this trial may help researchers understand physicians' knowledge about the diagnosis, prognosis…
- Trial name
- NCT04132440
- Testing
- Interview, Questionnaire Administration
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Inflammation, Fibrosis
Effect of Vitamin E on Pediatric Nonalcoholic Fatty Liver Disease (NAFLD)
No proven treatment exists for nonalcoholic fatty liver disease (NAFLD) in children and adolescents. We aim to determine the efficacy of lifestyle intervention with or without antioxidant therapy in pediatric NAFLD.
- Conditions
- Inflammation, Fibrosis, Insulin Resistance
- Trial name
- VITENAFLD (NCT00655018)
- Testing
- Vitamin treatment (alpha tocopherol plus ascorbic acid)
- Where
- Italy
- Volunteers
- 90 people
- Sponsor
- Bambino Gesù Hospital and Research Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.